KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Payables (2020 - 2025)

Historic Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $13.9 million.

  • Recursion Pharmaceuticals' Payables rose 51659.29% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 51659.29%. This contributed to the annual value of $21.6 million for FY2024, which is 44113.67% up from last year.
  • Recursion Pharmaceuticals' Payables amounted to $13.9 million in Q3 2025, which was up 51659.29% from $19.3 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Payables peaked at $25.1 million during Q1 2025, and registered a low of $2.3 million during Q3 2024.
  • Moreover, its 5-year median value for Payables was $4.9 million (2023), whereas its average is $7.6 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Payables plummeted by 5443.55% in 2024 and then soared by 51659.29% in 2025.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Payables stood at $2.9 million in 2021, then soared by 60.98% to $4.7 million in 2022, then dropped by 14.71% to $4.0 million in 2023, then surged by 441.14% to $21.6 million in 2024, then crashed by 35.52% to $13.9 million in 2025.
  • Its Payables stands at $13.9 million for Q3 2025, versus $19.3 million for Q2 2025 and $25.1 million for Q1 2025.